Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03630055 · ClinicalTrials.gov registry record · Phase 3
Rivaroxaban Post-Transradial Access for the Prevention of Radial Artery Occlusion
A Phase 3 study of Radial Artery Occlusion, sponsored by Ottawa Heart Institute Research Corporation.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 1,800
- Enrollment target
- 3
- Study locations
NCT03630055: Recruiting Phase 3 study of Radial Artery Occlusion, sponsored by Ottawa Heart Institute Research Corporation.
NCT03630055 is a Phase 3 study of Radial Artery Occlusion that is actively recruiting participants, run by Ottawa Heart Institute Research Corporation. The registered enrollment target is 1,800 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (133% higher). The trial reports 3 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03630055, a Phase 3 study of Radial Artery Occlusion, is actively recruiting participants, sponsored by Ottawa Heart Institute Research Corporation.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,800 participants
- Enrollment target
- 3
- Study locations
Study Summary
Coronary angiography is performed to evaluate for obstructive coronary artery disease. This is commonly performed via the transfemoral or transradial approach with the latter increasing in frequency. One of the most common complications of transradial access is radial artery occlusion occurring in \~5% of patients which prohibits the use of the radial artery in the future. There is evidence to support the use of intraprocedural anticoagulation to mitigate the risk of radial artery occlusion however the role of post-procedural anticoagulation has not been previously evaluated. Rivaroxaban is a direct oral anticoagulant (DOAC) with a safety profile superior to that of vitamin K antagonists. Given the safety profile, ease of use, and feasibility of DOAC therapy, our study will endeavor to evaluate the use of rivaroxaban 15mg orally once daily for 7 days after transradial access and the impact this has on the rate of radial artery occlusion.
Primary Outcome
Presence of radial artery occlusion at 30 days post-transradial access as determined by Doppler ultrasound assessment of the participant's radial artery in the wrist.
Conditions Studied
Interventions
- DRUG Rivaroxaban 15 MG Oral Tablet [Xarelto]
Study Locations (3)
Ontario
- Kingston Health Sciences Center - Kingston
- University of Ottawa Heart Institute - Ottawa
Minnesota
- Mayo Clinic - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,800 participants |
| Start Date | 2018-10-03 |
| Est. Completion | 2026-06-30 |
| Phase | Phase 3 |
What NCT03630055 shows while recruiting
NCT03630055 is an interventional study that assigns participants to a tested intervention. Its 1,800 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (133% higher).
The record links to 1 condition, with Radial Artery Occlusion appearing as the primary indexed condition, and to 1 intervention - of which Rivaroxaban 15 MG Oral Tablet [Xarelto] is the first listed.
NCT03630055 reports a single indexed study location in Ontario, Minnesota.
Frequently Asked Questions
What is clinical trial NCT03630055 about?
NCT03630055 is a clinical study titled "Rivaroxaban Post-Transradial Access for the Prevention of Radial Artery Occlusion". Coronary angiography is performed to evaluate for obstructive coronary artery disease. This is commonly performed via the transfemoral or transradial approach with the latter increasing in frequency. One of the most common complications of transradial access is radial artery occlusion occurring in \...
What is the current status of trial NCT03630055?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 1,800 participants. The study started on 2018-10-03. Estimated completion is 2026-06-30.
What conditions does trial NCT03630055 study?
This clinical trial studies the following conditions: Radial Artery Occlusion.
What interventions are being tested in trial NCT03630055?
The interventions under investigation include: Rivaroxaban 15 MG Oral Tablet [Xarelto] (DRUG).
Who is sponsoring clinical trial NCT03630055?
This trial is sponsored by Ottawa Heart Institute Research Corporation, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03630055 being conducted?
This trial has 3 study locations across Minnesota, Ontario. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03630055's enrollment target sits among peer trials
1,800 118th of 2000 higher than 1,877 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04475640 · 1,800 participants · NA
Cancer Genetic Testing in Ethnic Populations
- NCT04980794 · 1,800 participants · NA
The Happy Families Project: Testing the Effectiveness of a Conflict Resolution Program for Families
- NCT05258656 · 1,800 participants · NA
Childhood Activities Nutrition and Development Oversight
- NCT05286931 · 1,800 participants · NA
SpeeDx Ciprofloxacin gyrA Assay for N. Gonorrhoeae Gonococcal Infection
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI